应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
GILD 吉利德科学
盘后交易 06-30 19:55:36 EDT
126.34
+0.01
+0.01%
盘后
125.52
-0.82
-0.65%
19:18 EDT
最高
127.27
最低
124.19
成交量
740.95万
今开
125.88
昨收
126.33
日振幅
2.44%
总市值
1,567亿
流通市值
1,564亿
总股本
12.41亿
成交额
9.34亿
换手率
0.60%
流通股本
12.38亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜吉利德科学盘中上涨3.18%，Trodelvy获FDA批准用于三阴性乳腺癌一线治疗
行情直击 · 06-26
异动解读｜吉利德科学盘中上涨3.18%，Trodelvy获FDA批准用于三阴性乳腺癌一线治疗
FDA批准Sacituzumab Govitecan-hziy作为单药及与Pembrolizumab联合用于三阴性乳腺癌一线治疗
美股速递 · 06-25
FDA批准Sacituzumab Govitecan-hziy作为单药及与Pembrolizumab联合用于三阴性乳腺癌一线治疗
欧盟委员会批准Trodelvy®作为不适合Pd-(L)1抑制剂的转移性三阴性乳腺癌患者的一线治疗方案
美股速递 · 06-23
欧盟委员会批准Trodelvy®作为不适合Pd-(L)1抑制剂的转移性三阴性乳腺癌患者的一线治疗方案
异动解读｜吉利德科学盘中上涨3.06%，FDA接受Yeztugo每周一次口服HIV预防药物申请
行情直击 · 06-16
异动解读｜吉利德科学盘中上涨3.06%，FDA接受Yeztugo每周一次口服HIV预防药物申请
异动解读｜吉利德科学盘中上涨3.52%，HIV新药积极数据助力股价超跌反弹
行情直击 · 06-11
异动解读｜吉利德科学盘中上涨3.52%，HIV新药积极数据助力股价超跌反弹
国家艾滋病纪念园与吉利德基金会启动重大投资，扩展艾滋病教育与社区领导力
美股速递 · 06-11
国家艾滋病纪念园与吉利德基金会启动重大投资，扩展艾滋病教育与社区领导力
异动解读｜吉利德科学盘中下跌3.06%，Trodelvy肺癌三期试验终止持续施压
行情直击 · 06-11
异动解读｜吉利德科学盘中下跌3.06%，Trodelvy肺癌三期试验终止持续施压
异动解读｜吉利德科学盘中下跌3.29%，Trodelvy联合Keytruda肺癌三期试验宣布终止
行情直击 · 06-09
异动解读｜吉利德科学盘中下跌3.29%，Trodelvy联合Keytruda肺癌三期试验宣布终止
默沙东(MRK.US)与吉利德科学(GILD.US)联合HIV药物三期临床试验达主要终点
智通财经 · 06-09
默沙东(MRK.US)与吉利德科学(GILD.US)联合HIV药物三期临床试验达主要终点
吉利德科学：Islatravir/Lenacapavir HIV治疗方案在两项试验中均达到第48周主要疗效终点
美股速递 · 06-09
吉利德科学：Islatravir/Lenacapavir HIV治疗方案在两项试验中均达到第48周主要疗效终点
吉利德科学宣布两项评估口服每周一次HIV疗法Islatravir与Lenacapavir的三期研究取得积极顶线结果
美股速递 · 06-09
吉利德科学宣布两项评估口服每周一次HIV疗法Islatravir与Lenacapavir的三期研究取得积极顶线结果
吉利德与默克计划就伊斯拉曲韦/来那卡帕韦三期试验数据向全球监管机构提交申请
美股速递 · 06-09
吉利德与默克计划就伊斯拉曲韦/来那卡帕韦三期试验数据向全球监管机构提交申请
吉利德科学：Trodelvy与Keytruda联用的安全性特征与各药物已知安全性一致
美股速递 · 06-09
吉利德科学：Trodelvy与Keytruda联用的安全性特征与各药物已知安全性一致
吉利德科学宣布终止Trodelvy联合Keytruda的III期Keynote-D46/Evoke-03研究
美股速递 · 06-09
吉利德科学宣布终止Trodelvy联合Keytruda的III期Keynote-D46/Evoke-03研究
吉利德科学公布52周数据：ALP正常化率持续高位，安全性总体耐受良好
美股速递 · 06-02
吉利德科学公布52周数据：ALP正常化率持续高位，安全性总体耐受良好
吉利德科学旗下Livdelzi® (Seladelpar) 在原发性胆汁性胆管炎(PBC) III期IDEAL试验中实现具有统计学意义的复合ALP正常化
美股速递 · 06-02
吉利德科学旗下Livdelzi® (Seladelpar) 在原发性胆汁性胆管炎(PBC) III期IDEAL试验中实现具有统计学意义的复合ALP正常化
Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销
美股速递 · 06-02
Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销
异动解读｜吉利德科学盘中上涨3.04%，核心药物Trodelvy获欧盟CHMP积极意见
行情直击 · 05-23
异动解读｜吉利德科学盘中上涨3.04%，核心药物Trodelvy获欧盟CHMP积极意见
FDA批准Hepcludex注射剂用于治疗无肝硬化或代偿期肝硬化成人慢性丁型肝炎病毒感染
美股速递 · 05-23
FDA批准Hepcludex注射剂用于治疗无肝硬化或代偿期肝硬化成人慢性丁型肝炎病毒感染
吉利德科学Trodelvy®获欧盟CHMP积极意见，用于不适合PD-(L)1抑制剂患者的一线转移性三阴性乳腺癌治疗
美股速递 · 05-22
吉利德科学Trodelvy®获欧盟CHMP积极意见，用于不适合PD-(L)1抑制剂患者的一线转移性三阴性乳腺癌治疗
加载更多
公司概况
公司名称：
吉利德科学
所属市场：
NASDAQ
上市日期：
--
主营业务：
吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。
发行价格：
--
{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":126.34,"timestamp":1782849600000,"preClose":126.33,"halted":0,"volume":7409541,"hourTrading":{"tag":"盘后","latestPrice":125.5203,"preClose":126.34,"latestTime":"19:18 EDT","volume":603588,"amount":76257537.28344,"timestamp":1782861484400,"change":-0.8197,"changeRate":-0.006488,"amplitude":0.011554},"delay":0,"changeRate":0.00007915776141854758,"floatShares":1238162880,"shares":1240679623,"eps":7.352725,"marketStatus":"盘后交易","change":0.01,"latestTime":"06-30 19:55:36 EDT","open":125.88,"high":127.27,"low":124.19,"amount":934494052.4501699,"amplitude":0.024381,"askPrice":127.5,"askSize":35,"bidPrice":125.5,"bidSize":5,"shortable":3,"etf":0,"ttmEps":7.352725,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782864000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":126.33,"dividendRate":0.025249,"preHourTrading":{"tag":"盘前","latestPrice":125.78,"preClose":126.33,"latestTime":"09:29 EDT","volume":2137,"amount":268572.55251199997,"timestamp":1782826147058,"change":-0.55,"changeRate":-0.004354,"amplitude":0.018206},"postHourTrading":{"tag":"盘后","latestPrice":125.5203,"preClose":126.34,"latestTime":"19:18 EDT","volume":603588,"amount":76257537.28344,"timestamp":1782861484400,"change":-0.8197,"changeRate":-0.006488,"amplitude":0.011554},"volumeRatio":0.742005,"impliedVol":0.3084,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"1107662586","title":"异动解读｜吉利德科学盘中上涨3.18%，Trodelvy获FDA批准用于三阴性乳腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1107662586","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107662586?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:29","pubTimestamp":1782484183,"startTime":"0","endTime":"0","summary":"消息面上，美国FDA正式批准公司核心肿瘤药物Trodelvy用于晚期三阴性乳腺癌成人患者的一线治疗，包括作为单药疗法以及与默沙东Keytruda联合用药方案。美国国家综合癌症网络已更新指南，将Trodelvy列为转移性三阴性乳腺癌的1类首选一线治疗方案。此外，欧盟委员会也于近日批准Trodelvy用于不适合PD-1抑制剂治疗的转移性三阴性乳腺癌患者的一线治疗，全球监管进展顺利，进一步打开Trodelvy在乳腺癌领域的商业化空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181778029","title":"FDA批准Sacituzumab Govitecan-hziy作为单药及与Pembrolizumab联合用于三阴性乳腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1181778029","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181778029?lang=zh_cn&edition=full","pubTime":"2026-06-25 03:04","pubTimestamp":1782327863,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准Sacituzumab Govitecan-hziy作为单药疗法，以及与Pembrolizumab联合用药方案，用于三阴性乳腺癌患者的一线治疗。这一监管决定为这类侵袭性乳腺癌亚型患者提供了新的重要治疗选择。Sacituzumab Govitecan-hziy是一种靶向Trop-2抗原的抗体药物偶联物。此次FDA的批准基于一项关键临床试验的积极数据，该数据显示该疗法在延长患者无进展生存期和总生存期方面展现出潜力。这一批准标志着三阴性乳腺癌治疗领域的一个重要进展，有望改善患者的临床结局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU1430594728.SGD","LU1057294990.SGD","LU1571399168.USD","LU1934455277.USD","LU0114720955.EUR","BK4139","BK4566","LU1023059063.AUD","LU2468319806.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU0320765992.SGD","LU0882574055.USD","LU0234570918.USD","LU0965508806.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU1839511570.USD","SG9999015952.SGD","LU2087621335.USD","LU2112291526.USD","BK4550","IE0002270589.USD","SG9999015978.USD","LU0122379950.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU1934455863.HKD","BK4578","IE00B3T34201.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0965509101.SGD","LU0289739699.SGD","LU0965509010.AUD","LU1778281490.HKD","BK4568","SG9999015986.USD","LU0109394709.USD","BK4532","LU1585245621.USD","LU2324357040.USD","LU1037948541.HKD","LU0823416689.USD","LU2089984988.USD","LU1066053197.SGD","BK4583","LU0058720904.USD","LU1061106388.HKD","LU1066051498.USD","BK4588","SG9999015945.SGD","LU0889565916.HKD","BK4585","LU1037948897.HKD","LU1934455194.USD","GILD","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199544866","title":"欧盟委员会批准Trodelvy®作为不适合Pd-(L)1抑制剂的转移性三阴性乳腺癌患者的一线治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1199544866","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199544866?lang=zh_cn&edition=full","pubTime":"2026-06-23 19:45","pubTimestamp":1782215122,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准Trodelvy用于治疗不适合接受Pd-1抑制剂治疗的转移性三阴性乳腺癌患者，将其确立为首选的一线疗法。这一监管决定标志着针对这一难治性乳腺癌亚型患者群体的治疗格局取得了重要进展。随着监管批准的落地，医疗专业人士将能够为特定的转移性三阴性乳腺癌患者提供这一靶向Trop-2抗原的抗体药物偶联物作为初始系统性治疗方案，有望改善患者的临床结局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","BK4550","LU0320765992.SGD","LU2089984988.USD","BK4532","BK4568","LU1571399168.USD","SG9999015978.USD","BK4588","BK4583","LU1057294990.SGD","LU1066053197.SGD","LU0965509101.SGD","LU0889565916.HKD","LU1585245621.USD","LU1778281490.HKD","LU0109394709.USD","LU0234570918.USD","GILD","LU0122379950.USD","LU0058720904.USD","LU2087621335.USD","LU1066051498.USD","IE00B19Z3B42.SGD","LU1674673691.USD","LU2468319806.SGD","IE00B3T34201.USD","LU1037948541.HKD","LU1037948897.HKD","LU1061106388.HKD","IE00B19Z3581.USD","SG9999015952.SGD","LU0965509010.AUD","LU1674673428.USD","LU1934455863.HKD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0882574055.USD","LU1023059063.AUD","LU1839511570.USD","LU0289739699.SGD","LU2112291526.USD","LU1934455277.USD","IE0002270589.USD","IE00BKVL7J92.USD","LU1934455194.USD","LU1430594728.SGD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU0965509283.SGD","LU0114720955.EUR","LU2324357040.USD","BK4139","BK4585","LU0965508806.USD","LU0861579265.USD","BK4578","BK4566","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101683865","title":"异动解读｜吉利德科学盘中上涨3.06%，FDA接受Yeztugo每周一次口服HIV预防药物申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1101683865","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101683865?lang=zh_cn&edition=full","pubTime":"2026-06-16 23:43","pubTimestamp":1781624595,"startTime":"0","endTime":"0","summary":"6月16日，吉利德科学盘中上涨3.06%，报128.1美元/股，成交额2.87亿美元。消息面上，美国FDA已接受吉利德科学提交的Yeztugo300mg片剂的补充新药申请，用于每周一次口服HIV暴露前预防，PDUFA目标日期为明年2月2日。此外，此前公布的Islatravir/Lenacapavir每周一次口服HIV治疗方案两项三期试验均达主要终点，进一步夯实公司HIV管线优势。该股此前因Trodelvy肺癌三期试验终止而持续承压，HIV管线连续利好推动股价修复反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171165703","title":"异动解读｜吉利德科学盘中上涨3.52%，HIV新药积极数据助力股价超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1171165703","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171165703?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:58","pubTimestamp":1781186338,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中上涨3.52%，报125.095美元/股，成交额1.01亿美元。此前该股因Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期研究被终止而连续承压，累计跌幅显著。消息面上，吉利德科学与默沙东此前公布的HIV药物Islatravir/Lenacapavir口服每周一次治疗方案两项三期试验均达到第48周主要疗效终点，且不劣于必妥维和标准抗逆转录病毒疗法，两家公司计划向全球监管机构提交申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194875002","title":"国家艾滋病纪念园与吉利德基金会启动重大投资，扩展艾滋病教育与社区领导力","url":"https://stock-news.laohu8.com/highlight/detail?id=1194875002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194875002?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:34","pubTimestamp":1781181267,"startTime":"0","endTime":"0","summary":"国家艾滋病纪念园与吉利德基金会宣布，将启动一项重大投资项目，旨在显著扩展艾滋病相关的教育项目并加强社区的领导能力建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0889565916.HKD","SG9999015952.SGD","BK4532","LU1066053197.SGD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","SG9999015945.SGD","BK4588","LU1066051498.USD","IE00B7SZLL34.SGD","LU1934455863.HKD","LU0234570918.USD","LU0882574055.USD","LU0114720955.EUR","LU0823416689.USD","LU1057294990.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0122379950.USD","LU1934455277.USD","LU1037948541.HKD","LU0320765992.SGD","BK4585","BK4139","LU0965509283.SGD","LU1037948897.HKD","LU2087621335.USD","IE00BKVL7J92.USD","LU0965509010.AUD","LU2324357040.USD","BK4550","LU1934455194.USD","SG9999015978.USD","LU1778281490.HKD","LU1585245621.USD","LU1023059063.AUD","LU1061106388.HKD","LU0058720904.USD","GILD","LU0109394709.USD","LU2089984988.USD","LU1571399168.USD","LU0965509101.SGD","LU0861579265.USD","LU1674673428.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU1674673691.USD","BK4578","LU1430594728.SGD","LU1839511570.USD","SG9999015986.USD","BK4566","BK4583","LU0965508806.USD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167309488","title":"异动解读｜吉利德科学盘中下跌3.06%，Trodelvy肺癌三期试验终止持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167309488","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167309488?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:36","pubTimestamp":1781113006,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中下跌3.06%，报121.66美元/股，成交额5.19亿美元。消息面上，吉利德科学与默沙东此前宣布，基于数据监测委员会建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy作为吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。此外，加拿大皇家银行指出体内CAR-T早期技术可能威胁吉利德未来10%至15%的收入，进一步加剧市场担忧。同期公布的HIV药物Islatravir/Lenacapavir三期积极数据未能有效对冲肿瘤管线利空。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119573472","title":"异动解读｜吉利德科学盘中下跌3.29%，Trodelvy联合Keytruda肺癌三期试验宣布终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1119573472","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119573472?lang=zh_cn&edition=full","pubTime":"2026-06-09 22:07","pubTimestamp":1781014061,"startTime":"0","endTime":"0","summary":"6月9日，吉利德科学盘中下跌3.29%，报123.73美元/股，成交额1.6亿美元。消息面上，吉利德科学与默沙东宣布，基于数据监测委员会的建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy是吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。同日公布的HIV药物Islatravir/Lenacapavir三期积极数据未能对冲肿瘤管线利空。吉利德科学公司是一家以研究为基础的生物制药公司，主要聚焦病毒性疾病、炎性和纤维化疾病以及肿瘤学领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642545787","title":"默沙东(MRK.US)与吉利德科学(GILD.US)联合HIV药物三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642545787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642545787?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:47","pubTimestamp":1780987633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，默沙东和吉利德科学表示，含有默沙东药物伊斯拉曲韦和吉利德药物莱那卡帕韦的复方药片的两项 3 期试验的初步结果达到了主要终点。此外，研究发现 islatravir/lenacapavir不劣于必妥维和标准口服抗逆转录病毒疗法。此外，两家公司宣布，根据数据监测委员会的建议，他们将终止吉利德的 Trodelvy 与默沙东的Keytruda一线治疗转移性非小细胞肺癌的 3 期 KEYNOTE-D46/EVOKE-03 研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BN8TJ469.HKD","LU2491050154.USD","BK4139","SG9999002224.SGD","IE000M9KFDE8.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU1037948897.HKD","IE00B19Z3581.USD","LU2023250843.SGD","LU0889565916.HKD","SG9999002232.USD","LU1057294990.SGD","IE00BSNM7G36.USD","BK4585","LU1037948541.HKD","LU1941712264.USD","LU1035773651.USD","SG9999015978.USD","BK4550","LU1983299246.USD","SG9999015986.USD","LU0868494617.USD","IE00B4R5TH58.HKD","LU0211331839.USD","LU1162221912.USD","BK4566","LU1116320901.HKD","IE00BJJMRZ35.SGD","SG9999001176.USD","LU2361044949.HKD","BK4559","LU2089984988.USD","LU2357627491.SGD","LU1974910355.USD","IE0009355771.USD","LU1934455863.HKD","LU1839511570.USD","LU2491049909.HKD","LU0320765992.SGD","BK4583","LU1923622614.USD","LU0058720904.USD","LU0477156953.USD","IE00B1BXHZ80.USD","LU1934455277.USD","LU1291159041.SGD","LU1116320737.USD","LU2112291526.USD","LU0965508806.USD","SG9999013999.USD","LU2125909247.SGD","LU1066051811.HKD","IE00BFTCPJ56.SGD","MRK","SG9999014575.USD","LU0234570918.USD","BK4588","LU1674673691.USD","LU1571399168.USD","LU1066051225.USD","LU0320765489.SGD","LU0648001328.SGD","LU0265550359.USD","LU1934455194.USD","LU1941712348.USD","LU1066051498.USD","LU0980610538.SGD","LU1061106388.HKD","LU2461242641.AUD","LU0859254822.USD","LU0234572021.USD","BK4532","LU0965509283.SGD","LU2361044865.SGD","SGXZ57979304.SGD","LU1989772840.SGD","LU0098860793.USD","BK4516","LU1066053197.SGD","LU1699723380.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU0265550946.USD","LU2361045086.USD","GILD","LU0985320562.USD","LU2433249047.HKD","IE0002270589.USD","SG9999014542.SGD","IE00B7SZLL34.SGD","LU1069347547.HKD","LU0823416689.USD","LU1023059063.AUD","LU0203347892.USD","LU0106261372.USD","LU1917777945.USD","IE00BBT3K403.USD","LU0114720955.EUR","LU0203345920.USD","LU2125154935.USD","IE00B3T34201.USD","LU1585245621.USD","IE00BLSP4452.SGD","LU1929549753.HKD","LU0006306889.USD","LU2087621335.USD","BK4534","LU2360032135.SGD","LU0238689110.USD","LU2125909593.SGD","LU2491050071.SGD","IE00BJT1NW94.SGD","LU0266013472.USD","LU2023250504.SGD","LU0109394709.USD","BK4568","LU2324357040.USD","LU0432979614.USD","SG9999014567.USD","LU0208291251.USD","LU0942090050.USD","BK4578","LU0320765646.SGD","SG9999015358.SGD","LU0882574055.USD","SG9999015341.SGD","LU0122379950.USD","LU1674673428.USD","LU0289739699.SGD","LU1989771016.USD","SG9999015945.SGD","BK4007","LU0130102774.USD","LU1093756325.SGD","SG9999001176.SGD","LU0070302665.USD","IE00BLSP4239.USD","LU1093756168.USD","LU0965509010.AUD","SG9999014559.SGD","LU0868494708.USD","LU1201861249.SGD","BK4533","SG9999015952.SGD","LU2106854487.HKD","LU2125154778.USD","IE00B2B36J28.USD","SG9999001440.SGD","IE0002141913.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","LU0130517989.USD","LU1430594728.SGD","LU1989772923.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181239601","title":"吉利德科学：Islatravir/Lenacapavir HIV治疗方案在两项试验中均达到第48周主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1181239601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181239601?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951065,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，其基于islatravir与lenacapavir的HIV联合治疗方案，在两项关键临床试验中，均成功达到了预设的第48周主要疗效终点。这一积极结果标志着该创新疗法在抑制病毒载量方面展现出显著效果，为HIV感染者提供了潜在的全新长效治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001440.SGD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU0208291251.USD","LU1093756168.USD","LU1923622614.USD","LU0432979614.USD","IE000M9KFDE8.USD","LU1162221912.USD","LU1037948897.HKD","LU2361044949.HKD","LU1057294990.SGD","LU0823416689.USD","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","LU1201861249.SGD","LU1983299246.USD","LU0238689110.USD","LU2023250843.SGD","BK4533","LU0861579265.USD","LU2089984988.USD","SG9999001176.SGD","LU1066051498.USD","LU0965509101.SGD","LU2491050071.SGD","LU2357627491.SGD","LU1941712348.USD","LU0006306889.USD","SG9999015978.USD","LU0859254822.USD","LU2461242641.AUD","LU0266013472.USD","SGXZ57979304.SGD","LU0203347892.USD","IE0002270589.USD","LU1934455194.USD","SG9999015358.SGD","LU0106261372.USD","LU2125154778.USD","IE00B7SZLL34.SGD","LU0130102774.USD","LU1778281490.HKD","SG9999002224.SGD","LU1934455863.HKD","LU0098860793.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1116320737.USD","IE00BN8TJ469.HKD","LU2023250504.SGD","SG9999002232.USD","LU0648001328.SGD","LU0320765489.SGD","LU1989772840.SGD","LU2125909247.SGD","BK4550","LU0109394709.USD","LU1061106388.HKD","SG9999014575.USD","LU0265550946.USD","SG9999015986.USD","LU2468319806.SGD","LU2361044865.SGD","SG9999013999.USD","LU1934455277.USD","SG9999014542.SGD","BK4139","LU0265550359.USD","SG9999014567.USD","IE00B3T34201.USD","LU0965508806.USD","LU1839511570.USD","LU1037948541.HKD","LU1674673428.USD","LU0477156953.USD","LU2361045086.USD","BK4516","LU1585245621.USD","LU0122379950.USD","LU2106854487.HKD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU0320765992.SGD","LU1571399168.USD","LU1430594728.SGD","BK4007","LU1974910355.USD","SG9999015341.SGD","LU1917777945.USD","LU0058720904.USD","LU2087621335.USD","SG9999015945.SGD","LU0320765646.SGD","IE00BFTCPJ56.SGD","LU0980610538.SGD","BK4566","BK4583","LU0211331839.USD","LU0882574055.USD","LU1066053197.SGD","LU2360032135.SGD","LU2324357040.USD","LU0234570918.USD","LU1093756325.SGD","LU0070302665.USD","LU0985320562.USD","LU2125154935.USD","LU1066051225.USD","IE00BBT3K403.USD","MRK","LU1674673691.USD","BK4588","LU0234572021.USD","LU0114720955.EUR","IE00BSNM7G36.USD","LU2491050154.USD","LU1069347547.HKD","BK4585","LU1116320901.HKD","LU1989772923.USD","LU0203345920.USD","SG9999001176.USD","LU0868494708.USD","LU2491049909.HKD","LU1023059063.AUD","GILD","LU0868494617.USD","LU1929549753.HKD","LU2125909593.SGD","BK4559","LU2112291526.USD","LU1989771016.USD","IE00B19Z3581.USD","LU1066051811.HKD","LU1941712264.USD","IE0009355771.USD","LU0965509283.SGD","BK4568","LU2433249047.HKD","BK4534","LU1035773651.USD","IE00B2B36J28.USD","LU1699723380.USD","BK4578","LU1291159041.SGD","LU0942090050.USD","BK4532","SG9999015952.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","LU0130517989.USD","SG9999014559.SGD","IE00B4R5TH58.HKD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171410707","title":"吉利德科学宣布两项评估口服每周一次HIV疗法Islatravir与Lenacapavir的三期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1171410707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171410707?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951057,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，其针对口服、每周一次给药的HIV治疗药物Islatravir与Lenacapavir的两项三期临床研究，均获得了积极的顶线结果。这一进展标志着该创新型长效治疗方案在关键性试验阶段迈出了重要一步，有望为HIV感染者的治疗管理带来新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","BK4566","LU0109394709.USD","LU1934455277.USD","BK4568","LU1585245621.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0058720904.USD","LU0823416689.USD","IE0002270589.USD","BK4550","LU0289739699.SGD","BK4585","LU0965509010.AUD","LU1674673691.USD","LU2089984988.USD","LU2112291526.USD","SG9999015952.SGD","BK4583","LU0122379950.USD","IE00B7SZLL34.SGD","BK4532","LU1057294990.SGD","LU1066053197.SGD","LU0234570918.USD","LU1037948897.HKD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU1839511570.USD","BK4139","LU1934455863.HKD","LU1061106388.HKD","LU1778281490.HKD","GILD","IE00B19Z3581.USD","LU0320765992.SGD","LU1037948541.HKD","BK4588","LU1674673428.USD","IE00BSNM7G36.USD","LU2468319806.SGD","IE00B3T34201.USD","SG9999015945.SGD","LU0965509101.SGD","LU1023059063.AUD","LU0861579265.USD","LU2324357040.USD","IE00BKVL7J92.USD","LU0965508806.USD","LU0114720955.EUR","BK4578","LU1066051498.USD","LU1934455194.USD","SG9999015978.USD","LU0965509283.SGD","LU1571399168.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145372846","title":"吉利德与默克计划就伊斯拉曲韦/来那卡帕韦三期试验数据向全球监管机构提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1145372846","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145372846?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951047,"startTime":"0","endTime":"0","summary":"吉利德科学与其合作伙伴默克集团计划，将伊斯拉曲韦与来那卡帕韦联合用药的三期临床试验数据，提交给全球范围内的监管机构进行审评。此举标志着该候选药物在研发进程中迈出了关键一步，为其未来可能获批上市奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU2468319806.SGD","SG9999015945.SGD","IE0002270589.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU0320765992.SGD","MKGAF","LU0289739699.SGD","SG9999015978.USD","BK4583","BK4588","LU0109394709.USD","BK4007","LU1839511570.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0965508806.USD","SG9999015986.USD","LU0861579265.USD","LU1023059063.AUD","LU1674673691.USD","IE00BKVL7J92.USD","BK4585","LU0058720904.USD","LU0889565916.HKD","LU0965509010.AUD","LU1571399168.USD","LU1934455277.USD","LU1037948541.HKD","BK4568","LU0114720955.EUR","LU1066051498.USD","LU1934455194.USD","BK4532","LU0234570918.USD","LU1057294990.SGD","BK4139","IE00BZ1G4Q59.USD","LU0823416689.USD","LU0965509101.SGD","LU0965509283.SGD","BK4566","LU1430594728.SGD","SG9999015952.SGD","LU2089984988.USD","LU1934455863.HKD","LU1061106388.HKD","LU2087621335.USD","IE00BSNM7G36.USD","BK4550","LU1585245621.USD","LU1674673428.USD","LU1037948897.HKD","IE00B7SZLL34.SGD","LU0122379950.USD","LU1066053197.SGD","BK4578","GILD","LU2324357040.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164602486","title":"吉利德科学：Trodelvy与Keytruda联用的安全性特征与各药物已知安全性一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164602486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164602486?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:32","pubTimestamp":1780950760,"startTime":"0","endTime":"0","summary":"吉利德科学公司公布的数据显示，其抗体偶联药物Trodelvy与默沙东公司的Keytruda联合使用的安全性特征，与两种药物各自已知的安全性情况保持一致。这一发现为评估该联合疗法的潜力提供了重要的安全性基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU2106854487.HKD","LU1057294990.SGD","LU2125154935.USD","LU1066051811.HKD","BK4139","LU1116320737.USD","LU2357627491.SGD","LU1941712264.USD","SG9999013999.USD","LU1035773651.USD","LU0006306889.USD","LU2491049909.HKD","SGXZ57979304.SGD","LU0823416689.USD","IE00BFTCPJ56.SGD","BK4550","IE00B7SZLL34.SGD","SG9999015986.USD","LU0265550946.USD","LU1066053197.SGD","LU2491050071.SGD","LU1066051498.USD","LU0208291251.USD","SG9999015978.USD","LU0098860793.USD","LU1116320901.HKD","LU1917777945.USD","LU0320765489.SGD","LU2089984988.USD","LU1291159041.SGD","LU2468319806.SGD","LU0477156953.USD","LU0965509283.SGD","SG9999001440.SGD","LU0861579265.USD","BK4568","BK4585","IE00B3T34201.USD","LU1571399168.USD","LU0265550359.USD","SG9999014542.SGD","LU2361044865.SGD","LU0320765992.SGD","LU0070302665.USD","IE0002141913.USD","LU1934455863.HKD","LU0320765646.SGD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU2461242641.AUD","LU0289739699.SGD","LU1023059063.AUD","LU1674673691.USD","SG9999014559.SGD","SG9999015952.SGD","BK4534","IE00B1BXHZ80.USD","LU0238689110.USD","LU1069347547.HKD","LU0130517989.USD","BK4007","LU1162221912.USD","IE000M9KFDE8.USD","LU0130102774.USD","LU1989771016.USD","MRK","IE00BKVL7J92.USD","IE00B4R5TH58.HKD","BK4533","LU1061106388.HKD","BK4588","GILD","LU0122379950.USD","IE0002270589.USD","IE00BN8TJ469.HKD","LU0889565916.HKD","LU1934455277.USD","LU0965509010.AUD","LU2125154778.USD","LU0203347892.USD","IE00BJT1NW94.SGD","LU1989772923.USD","LU0965508806.USD","LU0114720955.EUR","LU0432979614.USD","LU0965509101.SGD","LU2023250504.SGD","LU2491050154.USD","IE00BSNM7G36.USD","LU1983299246.USD","SG9999014567.USD","BK4566","LU1778281490.HKD","IE0009355771.USD","SG9999015358.SGD","LU0985320562.USD","LU0980610538.SGD","LU0203345920.USD","LU0868494708.USD","LU1989772840.SGD","LU1674673428.USD","LU2361045086.USD","SG9999015945.SGD","LU0942090050.USD","LU0234570918.USD","SG9999001176.SGD","SG9999002232.USD","BK4532","LU1839511570.USD","LU0868494617.USD","SG9999001176.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU2087621335.USD","SG9999014575.USD","LU0109394709.USD","LU1066051225.USD","LU0211331839.USD","LU1037948541.HKD","LU1430594728.SGD","LU1699723380.USD","LU1093756168.USD","BK4583","LU2360032135.SGD","LU2112291526.USD","LU1585245621.USD","IE00B19Z3581.USD","LU1037948897.HKD","LU2324357040.USD","IE00BLSP4239.USD","LU0648001328.SGD","LU0058720904.USD","LU2433249047.HKD","LU0882574055.USD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU2361044949.HKD","LU1934455194.USD","SG9999015341.SGD","LU2125909247.SGD","IE00B19Z3B42.SGD","BK4578","BK4559","LU1923622614.USD","LU0859254822.USD","LU2125909593.SGD","LU1929549753.HKD","LU0106261372.USD","BK4516","LU1941712348.USD","SG9999002224.SGD","LU2023250843.SGD","LU0234572021.USD","LU1201861249.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197062628","title":"吉利德科学宣布终止Trodelvy联合Keytruda的III期Keynote-D46/Evoke-03研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1197062628","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197062628?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:31","pubTimestamp":1780950708,"startTime":"0","endTime":"0","summary":"吉利德科学已决定终止其III期临床试验Keynote-D46/Evoke-03。该研究旨在评估其药物Trodelvy与默沙东的Keytruda联合用药方案。\n此项研究的终止意味着该联合疗法的开发进程已告一段落。吉利德科学未在本次公告中披露终止该研究的详细原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","LU2461242641.AUD","LU2361044865.SGD","IE00BSNM7G36.USD","BK4559","LU1929549753.HKD","LU1917777945.USD","LU0889565916.HKD","IE00BLSP4239.USD","LU0432979614.USD","LU0265550359.USD","LU0965508806.USD","IE00B7SZLL34.SGD","LU2106854487.HKD","BK4007","LU1839511570.USD","BK4585","LU0203347892.USD","LU0234572021.USD","IE00BJJMRZ35.SGD","LU1941712348.USD","IE00B2B36J28.USD","SGXZ57979304.SGD","LU2125154935.USD","LU0823416689.USD","GILD","LU0965509283.SGD","LU0980610538.SGD","LU1989772923.USD","LU0985320562.USD","BK4532","LU1674673428.USD","BK4139","LU2491049909.HKD","SG9999015358.SGD","BK4578","LU0320765646.SGD","LU1093756168.USD","LU2361045086.USD","LU1934455863.HKD","SG9999015986.USD","IE0002141913.USD","IE0002270589.USD","SG9999014542.SGD","LU1983299246.USD","LU1069347547.HKD","IE00B19Z3581.USD","LU0098860793.USD","SG9999013999.USD","LU1023059063.AUD","BK4516","LU1571399168.USD","BK4566","BK4533","LU1989772840.SGD","LU2433249047.HKD","LU2361044949.HKD","SG9999014575.USD","LU0965509101.SGD","BK4534","IE00B3T34201.USD","LU1061106388.HKD","LU2023250504.SGD","IE00BZ1G4Q59.USD","IE00BJT1NW94.SGD","IE00BN8TJ469.HKD","SG9999002232.USD","LU2491050071.SGD","LU1116320901.HKD","LU1201861249.SGD","SG9999015341.SGD","LU0122379950.USD","LU2112291526.USD","LU0006306889.USD","LU1974910355.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0130102774.USD","LU2491050154.USD","LU2468319806.SGD","SG9999015945.SGD","LU2023250843.SGD","BK4583","LU0266013472.USD","LU2089984988.USD","SG9999015978.USD","LU1941712264.USD","LU0058720904.USD","LU1093756325.SGD","LU0861579265.USD","LU1066053197.SGD","LU1066051225.USD","IE00B4R5TH58.HKD","BK4588","LU0868494617.USD","SG9999014559.SGD","LU1116320737.USD","LU0265550946.USD","LU0114720955.EUR","MRK","LU2125154778.USD","LU1057294990.SGD","LU0211331839.USD","LU1989771016.USD","IE00BKVL7J92.USD","LU0130517989.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1934455277.USD","LU0320765489.SGD","LU0234570918.USD","LU0070302665.USD","LU1291159041.SGD","LU1699723380.USD","LU0106261372.USD","IE000M9KFDE8.USD","LU0238689110.USD","LU2357627491.SGD","LU2324357040.USD","IE00B1BXHZ80.USD","LU1778281490.HKD","LU2087621335.USD","LU0882574055.USD","SG9999014567.USD","LU0965509010.AUD","LU1674673691.USD","LU0208291251.USD","LU0477156953.USD","IE00B19Z3B42.SGD","LU1066051811.HKD","BK4568","SG9999015952.SGD","IE0009355771.USD","LU0868494708.USD","IE00BLSP4452.SGD","LU1430594728.SGD","LU0203345920.USD","LU2125909593.SGD","SG9999001176.SGD","LU0648001328.SGD","SG9999002224.SGD","SG9999001176.USD","LU1162221912.USD","LU1037948541.HKD","LU1066051498.USD","BK4550","LU0320765992.SGD","LU0859254822.USD","LU1037948897.HKD","SG9999001440.SGD","LU1585245621.USD","LU0942090050.USD","LU2125909247.SGD","LU1934455194.USD","LU1923622614.USD","LU1035773651.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154475153","title":"吉利德科学公布52周数据：ALP正常化率持续高位，安全性总体耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1154475153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154475153?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:35","pubTimestamp":1780403750,"startTime":"0","endTime":"0","summary":"吉利德科学最新发布的52周临床研究结果显示，其疗法展现出高且持续的血清碱性磷酸酶（ALP）正常化率。同时，该疗法的安全性特征总体良好，耐受性高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","IE00BKVL7J92.USD","IE0002270589.USD","LU0122379950.USD","LU1023059063.AUD","LU1037948897.HKD","LU2089984988.USD","BK4588","LU1571399168.USD","LU1934455277.USD","LU0965509283.SGD","LU0965509101.SGD","IE00BSNM7G36.USD","BK4532","LU1778281490.HKD","IE00B7SZLL34.SGD","LU0234570918.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1934455194.USD","LU1057294990.SGD","LU0882574055.USD","BK4550","SG9999015978.USD","IE00B19Z3B42.SGD","GILD","BK4568","LU2468319806.SGD","LU0109394709.USD","BK4566","LU0823416689.USD","LU1061106388.HKD","SG9999015986.USD","LU1839511570.USD","LU1430594728.SGD","LU2087621335.USD","LU1674673428.USD","BK4578","IE00B19Z3581.USD","LU0114720955.EUR","LU1585245621.USD","LU2324357040.USD","LU0861579265.USD","BK4583","BK4139","LU0965509010.AUD","LU0889565916.HKD","LU1674673691.USD","LU0965508806.USD","LU1066051498.USD","LU2112291526.USD","IE00B3T34201.USD","LU1934455863.HKD","LU1037948541.HKD","LU0058720904.USD","LU0320765992.SGD","BK4585","SG9999015945.SGD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155362957","title":"吉利德科学旗下Livdelzi® (Seladelpar) 在原发性胆汁性胆管炎(PBC) III期IDEAL试验中实现具有统计学意义的复合ALP正常化","url":"https://stock-news.laohu8.com/highlight/detail?id=1155362957","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155362957?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:30","pubTimestamp":1780403420,"startTime":"0","endTime":"0","summary":"吉利德科学公司研发的Livdelzi® (Seladelpar) 在针对原发性胆汁性胆管炎（PBC）的III期IDEAL临床试验中，取得了具有统计学意义的复合碱性磷酸酶（ALP）正常化结果。该积极数据标志着这款在研药物在治疗这一慢性肝病方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU1778281490.HKD","LU1061106388.HKD","LU0882574055.USD","LU1066053197.SGD","LU1839511570.USD","GILD","SG9999015986.USD","LU1585245621.USD","LU0114720955.EUR","LU1023059063.AUD","BK4532","LU1430594728.SGD","LU1674673691.USD","BK4139","BK4583","BK4568","LU0965508806.USD","LU1674673428.USD","SG9999015952.SGD","BK4566","SG9999015945.SGD","BK4588","LU0823416689.USD","LU0861579265.USD","LU0965509010.AUD","IE00B19Z3B42.SGD","BK4550","IE00BKVL7J92.USD","SG9999015978.USD","LU0965509101.SGD","LU1037948897.HKD","LU0289739699.SGD","LU0234570918.USD","LU1934455194.USD","LU0109394709.USD","BK4578","LU0889565916.HKD","LU1057294990.SGD","LU1934455863.HKD","LU1066051498.USD","LU2324357040.USD","IE00B19Z3581.USD","LU0058720904.USD","LU1571399168.USD","IE0002270589.USD","BK4585","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1934455277.USD","LU0965509283.SGD","IE00B3T34201.USD","LU2087621335.USD","LU0122379950.USD","LU0320765992.SGD","LU2112291526.USD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064750","title":"Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064750","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146064750?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:06","pubTimestamp":1780401987,"startTime":"0","endTime":"0","summary":"Cencora Inc.宣布与吉利德科学旗下公司Kite达成一项协议，将支持Kite旗下两款已获美国食品药品监督管理局批准的CAR-T细胞疗法——Yescarta与Tecartus——在美国市场的分销工作。该合作旨在强化这些创新癌症疗法的供应链与可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU1571399168.USD","LU1778281490.HKD","BK4568","IE00B3T34201.USD","LU0823416689.USD","BK4578","LU0861579265.USD","LU1934455863.HKD","BK4529","LU1084165304.USD","IE0002270589.USD","BK4566","LU0882574055.USD","LU0965508806.USD","LU0965509010.AUD","SG9999015986.USD","GILD","SGXZ23171101.USD","LU1061106388.HKD","LU1261432733.SGD","COR","LU1037948541.HKD","BK4175","LU1674673428.USD","LU1934455194.USD","LU2237957902.USD","BK4532","LU1066053197.SGD","IE00B7SZLL34.SGD","LU1674673691.USD","LU0114720955.EUR","LU1814569148.SGD","LU1934455277.USD","LU1585245621.USD","LU1066051498.USD","BK4550","LU0965509101.SGD","LU1839511570.USD","LU0965509283.SGD","BK4588","LU1430594728.SGD","IE00B19Z3581.USD","LU2324357040.USD","LU1023059063.AUD","LU2089984988.USD","LU0289739699.SGD","LU0109394709.USD","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999004303.SGD","SG9999015945.SGD","LU0122379950.USD","LU1037948897.HKD","IE00BSNM7G36.USD","LU0320765992.SGD","LU2468319806.SGD","BK4084","BK4139","LU0234570918.USD","LU0058720904.USD","LU0889565916.HKD","BK4585","LU1119994496.HKD","LU2087621335.USD","SG9999015978.USD","LU2237957811.SGD","SG9999015952.SGD","BK4583","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184286246","title":"异动解读｜吉利德科学盘中上涨3.04%，核心药物Trodelvy获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1184286246","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184286246?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:59","pubTimestamp":1779479951,"startTime":"0","endTime":"0","summary":"5月22日，吉利德科学盘中上涨3.04%，报134.47美元/股，成交额5.59亿美元。消息面上，吉利德科学宣布其抗体药物偶联物Trodelvy获得欧洲药品管理局人用药品委员会积极意见，支持批准其作为一线转移性三阴性乳腺癌疗法，用于不适合PD-1抑制剂治疗的患者。III期临床数据显示，Trodelvy较传统化疗将疾病进展或死亡风险降低38%，欧盟委员会最终决定预计年内作出。此外，公司已完成对德国Tubulis的31.5亿美元收购，进一步强化ADC布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129505357","title":"FDA批准Hepcludex注射剂用于治疗无肝硬化或代偿期肝硬化成人慢性丁型肝炎病毒感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1129505357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129505357?lang=zh_cn&edition=full","pubTime":"2026-05-23 01:38","pubTimestamp":1779471495,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Hepcludex注射剂，用于治疗未伴有肝硬化或处于代偿期肝硬化的成人慢性丁型肝炎病毒（HDV）感染。这一决定为患有这种严重肝脏疾病的患者群体提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU2324357040.USD","BK4139","LU1057294990.SGD","LU0965508806.USD","LU0320765992.SGD","LU1066051498.USD","LU0234570918.USD","GILD","LU1571399168.USD","LU1037948541.HKD","LU2112291526.USD","SG9999015945.SGD","LU1066053197.SGD","LU2087621335.USD","LU0882574055.USD","LU0861579265.USD","LU2468319806.SGD","IE00BSNM7G36.USD","LU1023059063.AUD","SG9999015986.USD","BK4550","LU0889565916.HKD","IE00B3T34201.USD","BK4588","BK4585","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1585245621.USD","BK4583","IE0002270589.USD","BK4566","LU0965509010.AUD","LU1674673428.USD","LU0114720955.EUR","LU0058720904.USD","IE00BKVL7J92.USD","LU0823416689.USD","SG9999015978.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673691.USD","LU0965509283.SGD","LU1037948897.HKD","LU2089984988.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","BK4532","LU1934455277.USD","LU1934455863.HKD","LU1839511570.USD","LU1934455194.USD","LU1778281490.HKD","BK4578","LU0122379950.USD","LU1430594728.SGD","LU0109394709.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189035839","title":"吉利德科学Trodelvy®获欧盟CHMP积极意见，用于不适合PD-(L)1抑制剂患者的一线转移性三阴性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1189035839","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189035839?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:49","pubTimestamp":1779450575,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，其药物Trodelvy获得了欧洲药品管理局人用药品委员会的积极意见。该意见支持批准Trodelvy用于治疗不适合接受PD-1抑制剂的患者群体，作为一线转移性三阴性乳腺癌的疗法。这一积极意见是基于关键的III期临床试验数据。研究结果表明，与医生选择的化疗相比，Trodelvy在无进展生存期和总生存期方面均显示出具有统计学意义和临床意义的改善。欧盟委员会在审查药品上市许可申请时，通常会采纳CHMP的意见，最终决定预计将在未来几个月内做出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4139","BK4568","IE00BZ1G4Q59.USD","LU2324357040.USD","LU1934455863.HKD","LU0861579265.USD","LU1839511570.USD","GILD","IE00BKVL7J92.USD","LU0320765992.SGD","LU0965509101.SGD","BK4583","IE0002270589.USD","BK4578","IE00B7SZLL34.SGD","LU0058720904.USD","LU1037948897.HKD","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU0122379950.USD","LU1023059063.AUD","LU1934455277.USD","LU1674673428.USD","LU0289739699.SGD","LU0889565916.HKD","SG9999015945.SGD","LU2112291526.USD","LU1057294990.SGD","IE00BSNM7G36.USD","BK4585","LU1037948541.HKD","LU0965509010.AUD","LU0965508806.USD","LU0114720955.EUR","SG9999015978.USD","BK4550","SG9999015986.USD","IE00B3T34201.USD","LU0234570918.USD","BK4588","LU1585245621.USD","LU1571399168.USD","LU1674673691.USD","LU2087621335.USD","SG9999015952.SGD","LU1934455194.USD","BK4566","LU1066051498.USD","LU1061106388.HKD","IE00B19Z3B42.SGD","LU2468319806.SGD","BK4532","LU0109394709.USD","LU0965509283.SGD","LU1430594728.SGD","LU2089984988.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":-0.0603},{"period":"3month","weight":-0.0936},{"period":"6month","weight":0.0292},{"period":"1year","weight":0.1415},{"period":"ytd","weight":0.0292}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.1394},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.2051},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.628571,"avgChangeRate":0.023218},{"month":7,"riseRate":0.558824,"avgChangeRate":0.01609},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}